110 related articles for article (PubMed ID: 3381006)
41. Malignant tumors in rats fed nafenopin, a hepatic peroxisome proliferator.
Reddy JK; Rao MS
J Natl Cancer Inst; 1977 Dec; 59(6):1645-50. PubMed ID: 200757
[TBL] [Abstract][Full Text] [Related]
42. Hypolipidemic effect of metrifonate and the relationship to serum cholinesterase inhibition.
Udom CE; Smith TJ
Res Commun Chem Pathol Pharmacol; 1991 Mar; 71(3):387-90. PubMed ID: 2047580
[TBL] [Abstract][Full Text] [Related]
43. Protein phosphorylation by peroxisome proliferators: species-specific stimulation of protein kinases and its role in PP-induced transcriptional activation.
Motojima K; Passilly P; Jannin B; Latruffe N
Ann N Y Acad Sci; 1996 Dec; 804():413-23. PubMed ID: 8993560
[No Abstract] [Full Text] [Related]
44. Arylesterase phenotype-specific positive association between arylesterase activity and cholinesterase specific activity in human serum.
Aoki Y; Helzlsouer KJ; Strickland PT
Int J Environ Res Public Health; 2014 Jan; 11(2):1422-43. PubMed ID: 24473115
[TBL] [Abstract][Full Text] [Related]
45. Serum carboxylesterase activity in various strains of rats: sensitivity to inhibition by CBDP (2-/o-cresyl/4H:1:3:2-benzodioxaphosphorin-2-oxide).
Clement JG; Erhardt N
Arch Toxicol; 1990; 64(5):414-6. PubMed ID: 2403290
[TBL] [Abstract][Full Text] [Related]
46. Protection against iron-induced uroporphyria in C57BL/10ScSn mice by the peroxisome proliferator nafenopin.
Smith AG; Francis JE; Walters DG; Lake BG
Biochem Pharmacol; 1990 Dec; 40(11):2564-8. PubMed ID: 2268375
[No Abstract] [Full Text] [Related]
47. Carbon tetrachloride toxicity in the rat after administration of hypolipidemic agents.
Burdino E; Crispino A; Di Carlo R; Genazzani E; Pagliarani M; Reboani C; Ugazio G
Panminerva Med; 1976; 18(11-12):410-4. PubMed ID: 995407
[No Abstract] [Full Text] [Related]
48. Response of microperoxisomes in rat small intestinal mucosa to CPIB, a hypolipidemic drug.
Svoboda DJ
Biochem Pharmacol; 1976 Dec; 25(24):2750-2. PubMed ID: 1008899
[No Abstract] [Full Text] [Related]
49. Cholinesterase, arylesterase, and lipoprotein parameters in twins.
Boman H
Acta Genet Med Gemellol (Roma); 1980; 29(4):281-7. PubMed ID: 7197453
[TBL] [Abstract][Full Text] [Related]
50. Effect of hypolipidemic drugs, nafenopin and clofibrate, on the concentration of ligandin and Z protein in rat liver.
Fleischner G; Meijer DK; Levine WG; Gatmaitan Z; Gluck R; Arias IM
Biochem Biophys Res Commun; 1975 Dec; 67(4):1401-7. PubMed ID: 812503
[No Abstract] [Full Text] [Related]
51. Arylesterases from various mammalian sera in relation to cholinesterases, carboxylesterases and their activity towards some pesticides.
Mendoza CE; Shields JB; Augustinsson KB
Comp Biochem Physiol C Comp Pharmacol; 1976; 55(1):23-6. PubMed ID: 8268
[No Abstract] [Full Text] [Related]
52. [Activity of arylesterase under normal conditions and in poisoning].
Malinin OA
Veterinariia; 1977 Jun; (6):92-4. PubMed ID: 929956
[No Abstract] [Full Text] [Related]
53. [Research on enzymes in the synovial fluid. Cholinesterase and arylesterase].
VINCENT D; ARLET J; SESQUE G; MARQUES-VINCENT MC
Pathol Biol; 1963 May; 11():580-6. PubMed ID: 13997331
[No Abstract] [Full Text] [Related]
54. Toxicological studies on gemfibrozil.
Kurtz SM; Fitzgerald JE; Fisken RA; Schardein JL; Reutner TH; Lucas JA
Proc R Soc Med; 1976; 69 Suppl 2(Suppl 2):15-23. PubMed ID: 828262
[No Abstract] [Full Text] [Related]
55. Clofibrate-induced decrease in esterase 1 levels in the serum of the house mouse, Mus musculus.
de Looze S; Ronai A; von Deimling O
Biochem Pharmacol; 1983 Jul; 32(13):2122-4. PubMed ID: 6870940
[No Abstract] [Full Text] [Related]
56. Studies on aromatic esterase and cholinesterase of human serum.
MARTON A; KALOW W
Can J Biochem Physiol; 1959 Nov; 37():1367-73. PubMed ID: 14421868
[No Abstract] [Full Text] [Related]
57. [On the esterases of human blood platelets (cholinesterase and arylesterase)].
VINCENT D; MAUPIN B; MARQUES-VINCENT MC
C R Seances Soc Biol Fil; 1962; 156():34-6. PubMed ID: 13926065
[No Abstract] [Full Text] [Related]
58. Suitability of laboratory animals for screening anti-hyperlipidemic agents.
Rajwade N; Desai NK; Joshi VG; Satoskar RS
J Postgrad Med; 1989 Jul; 35(3):162-70. PubMed ID: 2634757
[TBL] [Abstract][Full Text] [Related]
59. [Multiple forms of the esterases of carboxylic acid esters in myocardial infarct].
Surinov BP; Karpova NA; Rumiantseva IA
Vopr Med Khim; 1979; 25(5):579-82. PubMed ID: 494543
[No Abstract] [Full Text] [Related]
60. Animal models for screening hypolipidemic agents. I. Response to clofibrate in NMRI-mice of different body-weights.
Magnusson O
Z Versuchstierkd; 1978; 20(1):35-40. PubMed ID: 636681
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
